{
  "title": "Immuno Oncology Assays Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)",
  "slug": "immuno-oncology-assays-market",
  "industry": "Diagnostics & Monitoring",
  "parent_industry": "Healthcare (Pharma, Medical Devices, Biotech)",
  "url": "https://www.mordorintelligence.com/industry-reports/immuno-oncology-assays-market",
  "scraped_at": "2026-09-17T17:44:42+07:00",
  "dataset_properties": [
    {
      "@type": "PropertyValue",
      "name": "Market Size (2026)",
      "value": 6.77,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Size (2031)",
      "value": 11.87,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Growth Rate (2026 - 2031)",
      "value": 11.88,
      "unitText": "PERCENT"
    },
    {
      "@type": "PropertyValue",
      "name": "Fastest Growing Market",
      "value": "Asia Pacific"
    },
    {
      "@type": "PropertyValue",
      "name": "Largest Market",
      "value": "North America"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Concentration",
      "value": "Medium"
    }
  ],
  "faq": [
    {
      "@type": "Question",
      "name": "What is the projected value of the immuno-oncology assays market by 2031?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The market is forecast to reach USD 11.87 billion by 2031, advancing at a 11.88% CAGR."
      }
    },
    {
      "@type": "Question",
      "name": "Which product category contributes the most revenue today?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Reagents & Antibodies lead with 39.65% of global revenue, reflecting the consumable-intensive nature of immune profiling workflows."
      }
    },
    {
      "@type": "Question",
      "name": "What technology segment is growing the fastest?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Multiplex spatial profiling is expanding at a 12.48% CAGR as laboratories adopt single-cell, context-rich analysis platforms."
      }
    },
    {
      "@type": "Question",
      "name": "Why are companion diagnostics gaining momentum?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Recent FDA approvals for assays targeting MET, KRAS G12C, and TROP2 validate multi-parameter testing and are pushing the companion diagnostic segment toward a 12.44% CAGR."
      }
    },
    {
      "@type": "Question",
      "name": "How significant is liquid biopsy to future growth?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Liquid biopsy tests, used for non-invasive monitoring of circulating tumor DNA, are expected to grow at a 12.46% CAGR and complement tissue-based assays."
      }
    },
    {
      "@type": "Question",
      "name": "Which region offers the highest growth potential?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Asia-Pacific is projected to post a 12.55% CAGR through 2031, driven by rising cancer incidence, expanding screening programs, and streamlined regulatory pathways."
      }
    }
  ],
  "images": [
    "images/immuno-oncology-assays-market-size-image-1775122084938.png",
    "images/immuno-oncology-assays-market_1666703563941_Screenshot_2022-10-25_184224.png",
    "images/immuno-oncology-assays-market-Immuno-Oncology-Assays-Market-Market-Share-by-Product-2025-1768472273853.png",
    "images/immuno-oncology-assays-market-Immuno-Oncology-Assays-Market-Market-Share-by-Indication-2025-1768472278161.png",
    "images/immuno-oncology-assays-market-Immuno-Oncology-Assays-Market-CAGR--Growth-Rate-by-Region-2026---2031-1768472282466.png",
    "images/immuno-oncology-assays-market-competitive-landscape-1751890892717.png",
    "images/market-snapshot.png",
    "images/pdf3.png",
    "images/Esomar-25.png",
    "images/GPTW-25-3xl.png",
    "images/immuno-oncology-assays-market-size-image-1775122084938.png"
  ],
  "sections_count": 11
}